Intercure Ltd Dossier - Source-backed chat

Intercure Ltd

INCRNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.73

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.37Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $80.6M

Enterprise Value $185.3M

Shares Outstanding 15M diluted

Next Earnings Date15 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

InterCure Ltd. represents a compelling recovery and international expansion play within the global medical cannabis sector. Despite severe operational disruptions caused by the October 7, 2023, attacks on its primary southern Israeli facility (Nir Oz), the company has demonstrated remarkable resilience. InterCure successfully resumed production at Nir Oz, secured significant government compensation advances, and achieved record FY2025 revenues of NIS 270 million (a 13% year-over-year increase). Crucially, the company maintained its track record of profitability with its twelfth consecutive half-year of positive Adjusted EBITDA, which surged over 90% to NIS 47 million in FY2025. With the successful closing of the first tranche of the Botanico (ISHI) acquisition, exclusive access to premium U.S. genetics, and accelerating top-line momentum in the newly liberalized German medical market, InterCure is well-positioned to transition from domestic recovery to high-margin global growth.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The bear case reflects prolonged geopolitical instability in Israel, delays or shortfalls in receiving the remaining war damage compensation, and slower-than-expected patient acquisition in Germany. Additionally, failure to regain compliance with Nasdaq's minimum bid price could lead to delisting, severely reducing stock liquidity and depressing valuation multiples.

Base CaseCentral scenario

$1.2050%

The base case projects steady domestic recovery as the Nir Oz facility returns to pre-war capacity, coupled with moderate, disciplined expansion in Germany. The company successfully maintains positive Adjusted EBITDA and positive operating cash flows, while gradually resolving its Nasdaq minimum bid price compliance. Valuation multiples expand moderately from depressed historical lows as profitability stabilizes.

Bull CaseUpside scenario

$1.8030%

The bull case assumes rapid market share capture in Germany following regulatory liberalization, swift integration of Botanico's premium U.S. genetics and AI-driven cultivation technologies, and full recovery of the remaining NIS 169 million in war-related damages from Israeli authorities. This would dramatically improve gross margins, accelerate positive operating cash flows, and drive a significant valuation re-rating as the company establishes itself as a dominant medical cannabis platform across Europe and Israel.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proven operational resilience with the successful restart of the war-damaged Nir Oz facility.
Twelfth consecutive half-year of positive Adjusted EBITDA, demonstrating superior cost control and business model durability compared to unprofitable peers.
Strategic international growth catalysts, highlighted by early revenue generation in Germany and the acquisition of Botanico (ISHI) for premium U.S. genetics and AI tech.
Strong government backing, with NIS 82 million in compensation advances received to date against a NIS 251 million claim.

Key Investment Risks

Geopolitical and security risks associated with operating primary cultivation facilities in southern Israel near the Gaza border.
Regulatory compliance risk, specifically the ongoing Nasdaq notification regarding the minimum bid price requirement.
Agricultural risks, including crop failure, quality consistency, and strict pharmaceutical-grade GMP certification standards.

Thesis Invalidation Triggers

Delisting from the Nasdaq Capital Market due to failure to meet the minimum bid price requirement.
A material downward adjustment or denial of the remaining NIS 169 million war damage compensation claim by Israeli authorities.
Severe operational setbacks or renewed physical damage to the Nir Oz facility due to escalating regional conflict.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.